MLTX · MoonLake Immunotherapeutics

$16.74 +0.40 (+2.45%) At close · Aug 19

Market Cap

$1.39B

85.11M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Jorge Santos da Silva	Chief Executive Officer and Interim Chair of the Board	$762,386	—	$4,000,021	—	—	$24,922	$4,943,209
Dr. Kristian Reich	Chief Scientific Officer	$762,386	—	—	$4,000,021	—	$33,086	$4,795,493
Matthias Bodenstedt	Chief Financial Officer	$603,555	—	$4,000,021	—	—	$22,977	$4,692,576

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Jorge Santos da Silva	Chief Executive Officer	$698,245	$574,254	—	—	—	$23,626	$1,406,038
Dr. Kristian Reich	Chief Scientific Officer	$698,245	$574,254	—	—	—	$30,440	$1,302,939
Matthias Bodenstedt	Chief Financial Officer	$552,777	$413,289	—	—	—	$21,802	$1,032,555

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Kristian Reich	Chief Scientific Officer	$586,333	$589,819	—	—	—	$54,752	$1,230,904
Dr. Jorge Santos da Silva	Chief Executive Officer	$586,333	$589,819	—	—	—	$22,063	$1,198,215
Matthias Bodenstedt	Chief Financial Officer	$446,837	$424,491	—	—	—	$20,269	$891,597

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Matthias Bodenstedt	Chief Financial Officer	$324,900	$243,675	$5,044,225	—	—	$19,670	$5,632,470
Dr. Kristian Reich	Chief Scientific Officer	$460,275	$632,878	$3,362,817	—	—	$109,786	$4,565,756
Dr. Jorge Santos da Silva	Chief Executive Officer	$460,275	$632,878	$3,362,817	—	—	$21,411	$4,477,381

Executive changes

Person	Role	Change	Effective	Filed
Spike Loy	Class I Director Nominee	Appointed	2026-06-04	2026-06-09
Spike Loy	Lead Independent Director	Appointed	2026-02-28	2026-02-23
Jorge Santos da Silva	Interim Chair of the Board	Appointed	2026-02-28	2026-02-23
Simon Sturge	member of the Board	Resigned	2026-02-28	2026-02-23
Dr. Kara Lassen	member of the Board	Resigned	2024-12-31	2024-12-18
Ramnik Xavier	Director	Appointed	2022-04-05	2022-04-11
Jorge Santos da Silva	Director	Appointed	2022-04-05	2022-04-11
Kara Lassen	Director	Appointed	2022-04-05	2022-04-11
Andrew Phillips	Director	Appointed	2022-04-05	2022-04-11
Andrew J. Phillips	officers	Resigned	—	2022-04-11
Bihua Chen	officers	Resigned	—	2022-04-11
Nancy Chang	directors	Resigned	—	2022-04-11
John Schmid	directors	Resigned	—	2022-04-11
Will Lewis	directors	Resigned	—	2022-04-11
Bihua Chen	directors	Resigned	—	2022-04-11
Simon Sturge	Chairperson, Director	Appointed	2022-04-05	2022-04-11
Dr. Jorge Santos da Silva	Class III Director	Appointed	2022-04-05	2022-04-11
Dr. Andrew Phillips	Class III Director	Appointed	2022-04-05	2022-04-11
Catherine Moukheibir	Class II Director	Appointed	2022-04-05	2022-04-11
Spike Loy	Class I Director	Appointed	2022-04-05	2022-04-11
Dr. Ramnik Xavier	Class II Director	Appointed	2022-04-05	2022-04-11
Matthias Bodenstedt	Chief Financial Officer	Appointed	2022-04-05	2022-04-11
Dr. Kristian Reich	Chief Scientific Officer	Appointed	2022-04-05	2022-04-11
Dr. Kara Lassen	Class I Director	Appointed	2022-04-05	2022-04-11
Dr. Andrew J. Phillips	officer	Resigned	2022-04-05	2022-04-11

Key facts CIK 1821586 CUSIP 61559X104 13F (30d) 173 filings 167 filers Visit website Investor relations